Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING

Smoldering Inflammation in MS

NCT06591429 · View on ClinicalTrials.gov ↗

Study Summary

The goal of this observational study is to learn about inflammation in those with relapsing remitting Multiple Sclerosis (MS). The main questions it aims to answer are: * How does abnormal neural inflammation compare to cellular and molecular inflammation in MS? * Once treated, why does abnormal inflammation persist?

Conditions Studied

Interventions

  • RADIATION Radiotracer [11C]-CS1P1
  • RADIATION Radiotracer [11C]-DPA-713
  • DRUG anti-CD20 MS treatment
  • RADIATION Radiotracer [12F]-FDG

Study Locations (1)

Missouri

  • Barnes Jewish Center for Clinical Imaging Research — St Louis

Trial Details

FieldValue
Enrollment Target 25 participants
Start Date 2024-06-19
Est. Completion 2027-06-30

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06591429

The ClinicalTrials.gov registry entry for NCT06591429 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,036 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 4 interventions — of which Radiotracer [11C]-CS1P1 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT06591429 reports 1 study location spanning 1 distinct geographic area — top geographies include Missouri. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT06591429 about?

NCT06591429 is a clinical study titled "Smoldering Inflammation in MS". The goal of this observational study is to learn about inflammation in those with relapsing remitting Multiple Sclerosis (MS). The main questions it aims to answer are: * How does abnormal neural inflammation compare to cellular and molecular inflammation in MS? * Once treated, why does abnormal in...

What is the current status of trial NCT06591429?

This trial is currently recruiting. The enrollment target is 25 participants. The study started on 2024-06-19. Estimated completion is 2027-06-30.

What conditions does trial NCT06591429 study?

This clinical trial studies the following conditions: Multiple Sclerosis. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT06591429?

The interventions under investigation include: Radiotracer [11C]-CS1P1 (RADIATION), Radiotracer [11C]-DPA-713 (RADIATION), anti-CD20 MS treatment (DRUG), Radiotracer [12F]-FDG (RADIATION). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT06591429?

This trial is sponsored by Washington University School of Medicine, which has 1,036 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT06591429 being conducted?

This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial